Ticker League

EBITDA for STERIS (STE)

Latest filings through · Reported

Metric

TTM

$1.35B

YoY change

-18.5%

5Y CAGR

+7.4%

Peak year (2024)

$1.41B

EBITDA history chart for STERIS (STE) from 1991 to 2026

Latest: $1.11B

EBITDA growth chart for STERIS (STE) from 1991 to 2026

Latest: -18.5%

EBITDA history table for STERIS (STE) from 1991 to 2026

  • 2026$1.11B-18.5%
  • 2025$1.36B-3.8%
  • 2024$1.41B+5.1%
  • 2023$1.34B+33.1%
  • 2022$1.01B+30.4%
  • 2021$773.95M+5.1%
  • 2020$736.27M+15.0%
  • 2019$639.97M+9.6%
  • 2018$583.94M+39.9%
  • 2017$417.31M+16.5%
  • 2016$358.33M+12.1%
  • 2015$319.55M+13.0%
  • 2014$282.80M-9.3%
  • 2013$311.86M+9.0%
  • 2012$286.08M+104.0%
  • 2011$140.21M-46.3%
  • 2010$261.20M+10.8%
  • 2009$235.82M+16.9%
  • 2008$201.78M-1.3%
  • 2007$204.54M+6.0%
  • 2006$192.93M+0.2%
  • 2005$192.54M+8.5%
  • 2004$177.44M+3.0%
  • 2003$172.28M+35.1%
  • 2002$127.50M+8.7%
  • 2001$117.32M+69.1%
  • 2000$69.38M-59.1%
  • 1999$169.70M+24.0%
  • 1998$136.90M+35.7%
  • 1997$100.90M+12.7%
  • 1996$89.50M+6.2%
  • 1995$84.30M+869.0%
  • 1994$8.70M+222.2%
  • 1993$2.70M+1250.0%
  • 1992$200.00K-50.0%
  • 1991$400.00K—

EBITDA values are taken from STERIS's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.

About EBITDA at STERIS (STE)

According to STERIS's latest reported financial statements, the company's current EBITDA (TTM) is $1.35B. EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a common proxy for operating cash generation that strips out non-cash charges (depreciation and amortization) and capital structure effects (interest, taxes). Useful for comparing companies with different leverage and asset bases — see operating income and net income for fully GAAP figures.

Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .

As of the 2026 fiscal year, STERIS (STE) reported EBITDA of $1.11B – declined 18.5% year-over-year.

Across 2021–2026 (5 years), STERIS EBITDA produced a CAGR of +7.4% – with mixed annual results across the window.

STERIS EBITDA peaked at $1.41B in 2024; the latest annual figure is $1.11B in 2026 (21.6% below peak).

2024 marks the peak EBITDA at $1.41B, with the historical low of $200.00K recorded in 1992.

STERIS EBITDA by Year

STERIS EBITDA 2026: $1.11B

2026's EBITDA for STERIS came in at $1.11B, declined 18.5% below 2025.

STERIS EBITDA 2025: $1.36B

STERIS posted EBITDA of $1.36B in 2025, edged down 3.8% below 2024.

STERIS EBITDA 2024: $1.41B

In 2024, STERIS reported EBITDA of $1.41B, grew 5.1% from 2023. This figure represents the highest annual value in the available history.

STERIS EBITDA 2023: $1.34B

STERIS EBITDA in 2023 was $1.34B, surged 33.1% from 2022.

STERIS EBITDA 2022: $1.01B

STERIS EBITDA in 2022 was $1.01B.

See more financial history for STERIS (STE).

Sector peers by EBITDA

Healthcare peers of STERIS (STE), ranked by their latest EBITDA

Frequently asked questions

STERIS (STE) Key Financials

Charts, filings, and peer comparison for every metric

Explore more

Deep-dives across the income statement, cash flow, capital return, and valuation

Overview